Extended realease methylphenidate (medikinet®) twice a day, a prospective open trial
Downloads
Published
2012-03-30
How to Cite
Montañés Rada, F., Martínez Granero, M. A., Vidal Fermoso, M., Sanchez Romero, S., & Andrés Prado, M. J. (2012). Extended realease methylphenidate (medikinet®) twice a day, a prospective open trial. Revista De Psiquiatría Infanto-Juvenil, 29(1), 50–58. Retrieved from https://aepnya.eu/index.php/revistaaepnya/article/view/241
Issue
Section
Orginial article
Keywords:
ADHD, extended release methylphenidate, medikinet®, 8 hours, posology, open prospective study, efficacy, tolerabilityAbstract
The first study in which an 8 hours extended release methylphenidate 50/50 (medikinet®) is given twice a day to children is presented. As an open prospective study 60 consecutive admissions to a child psychiatric consultation that need methylphenidate from 8 to 21 hours and were not suitable to be given a short action methylphenidate (4 hours), where offered medikinet® twice a day with the following posology: a fixed dose of 30 mg in breakfast (8:00 hours) and either 10 mg (n=34) or 20 mg (n=6) at evening (15:00 hours). There were no significant differences between the 40 patients included in the study and the 20 patients that refused medikinet® twice a day. Patients were either moderate or severe in symptoma tology according to the 20 items Conners Scale for teachers (>45). At week 8 complete remission were reached for 63% patients (syndromic one for 12.5% , symptomatic one for 25% and functional one for 22,5%) Furthermore, 27,5% reached partial remission (decrease of at least 25% of symptoms). Scores in all subscales for Eyberg, Conners (Parents and Teachers) were reduced till level of normal population (except for conduct subscale of Teachers´) in a statistical significant level (p<0.05). Due to insomnia 2 patients reduced doses of 50/50- MTF to 10 mg and 3 drew up medikinet in the evening.
Downloads
Download data is not yet available.
References
1. Scottish Intercollegiate Guidelines Network. Management of attention deficit and Hyperkinetic disorders in children and young people. A National clinical guideline 112. Edimburgo; Oct 2009. [Consultado: 10/06/10]. http://www.sign.ac.uk/ pdf/sign112.pdf
2. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. (Clinical guideline; no. 72). London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Sep. 59 p. http://guidance.nice.org.uk/CG72
3. Reason R; Working Party of the British Psychological Society. ADHD: a psychological response to an evolving concept. Report of a Working Party of the British Psychological Society. J Learn Disabil. 1999;32(1):85-91.
4. Report of a Working Party of The British Psychological Society. Attention Deficit/ Hyperactivity Disorder (AD/HD): Guidelines and principles for successful multi-agency working. Leicester UK: The British Psychological Society; 2000.
5. Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). Royal Australasian College of Psysicians. June 2009. [Consultado: 10/06/10]. http://www.nhmrc.gov.au/publications/ synopses/adhd_draft.htm
6. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, 1re édition, Toronto (ON), CADDRA, 2006. http://www.caddra.ca/ joomla/index.php?Itemid=70 / http://www.caddra. ca/cms4/index.php?option=com_content&view=a rticle&id=26&Itemid=353&lang=en
7. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology SAGE Publications Ltd. London http://www. bap.org.uk/docsbycategory.php?docCatID=2
8. Evidence Based Clinical Practice Guideline for Outpatient Evaluation and Management of Attention Deficit/Hyperactivity Disorder Guideline 27. Cincinnati Children’s Hospital Medical Center, Cincinnaty 2007. http://www.cincinnatichildrens. org/svc/alpha/h/health-policy/ev-based/adhd.htm
9. E. Taylor, M. Döpfner, J., P. Asherson, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, A. Rothenberger, E. Sonuga-Barke, H.-C. Steinhausen and A. Zuddas. Eur Child Adolesc Psychiatry 2004; [Suppl 1] 13:I/7–I/30.
10. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105(5): 1158-70.
11. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity, Disorder Committee on Quality, Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108(4): 1033-44.
12. Pliszka S in name of AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7):894-921
13. Winters NC, Pumariga A, Work Group on Community Child and Adolescent Psychiatry, Work Group on Quality Issues. Practice parameter on child and adolescent mental health care in community systems of care. J Am Acad Child Adolesc Psychiatry 2007; 46(2): 284-99.
14. Steiner H, Remsing L, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(1):126-41.
15. Plisszka S, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, et al and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-deficit/ Hyperactivity Disorder. The Texas Childrens Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/ Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2006; 45(6):642-657.
16. ICSI. Institute for Clinical Systems Improvements. ADHD, Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents, Diagnosis and Management (Guideline) 2007. (Actualizado 04/2010) [Consultado: 10/06/10]: http://www.icsi.org/adhd/adhd_2300. html
17. O’Brian JM, Felt BT, Van Harrison R, Paramjeet KA, Riolo SA, Shehab N. UMHS. University of Michigan Health System. Guidelines for Clinical Care: Attention-Deficit Hyperactivity Disorder. 2005. [Consultado: 10/06/10]. Disponible en: http://cme.med.umich.edu/pdf/guideline/ ADHD05.pdf
18. Sentara Behavioral Health Services Guideline for the Recognition of ADHD in Adults. Sentara Healthcare (SHC). Virginia VA. 2006.
19. Quick Reference Guide. Recommended Screening and Medication Treatment Guidelines for Child and Adolescent Patients with Attention Deficit Hyperactivity Disorder (ADHD). Albuquerque, New Mexico: Lovelace Health Plan and Presbyterian Health Plan: 2007. http://aappolicy.aappublications. org/cgi/reprint/pediatrics;105/5/1158.pdf
20. Du Paul GJ. ADHD identification and assessment: basic Guidelines for educators. Helping Children at Home and School II: Handouts for Families and Educators S8–17. National Association of School Psychologists. Bethesda, MD 2004. www.nasponline. org
21. Montañés-Rada F, Gangoso-Fermoso AB, Martinez- Granero MA. Fármacos para el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 48: 469-81.
22. Montañés-Rada F, Gastaminza Pérez X, Catalá MA et al. Consenso del grupo GEITDAH sobre el trastorno por déficit de atención/hiperactividad. Rev Neurol 2010; 51: 633-7.
23. Rosler M, Fischer R, Ammer R, Ose C, Retz W, on behalf of the study group A randomised, placebocontrolled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attentiondeficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009; 259(2):120-9. epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009;259(6):368.
24. Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13(Suppl l):193-l0l
25. Banaschevski T, Coghill D, Santosh P, et al. Longacting medication for the hiperkinetic disorder. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15: 476- 9.
26. Conners CK, Erhardt D, Sparrow E . CAARS Conners adult ADHD rating scales. 1999. MHS, New York
27. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV. 1998. Guilford, New York
28. Eyberg SM, Robinson EA. Conduct Problem Behavior: Standarization of a behavioural rating scale with adolescents. J Clin Child Psychology. 1983; 12(3) 347-354.
29. Eyberg SM, Ross AW. Assesement of Child Behaviour Problems: The Validation of a New Inventory. J Clin Child Psychology. 1978; (summer): 113-116.
30. Robinson EA, Eyberg SM, Ross AW. The standardization of an inventory of child conduct problems behaviors. J Clin Child Psychology. 1980; (spring) 22-28.
31. Farre-Riba A y Narbona J. Escalas de Conners en la evaluación del trastorno por deficit de atención con hiperactividad: Nuevo estudio factorial en niños españoles. Rev Neurol. 1997; 25 (138): 200- 204.
32. Amador Campos JA. Idiazbal Alecha MA, Aznar Casanova A,Peró Cebollero M. Estructura factorial de la escala de Conners para profesores en muestras comunitaria y clínica. Revista de Psicología General y Aplicada. 2003: 56 (2) 173.184.
33. Fernández de Pinedo R, Gorostiza Garaya E, LAfuente Mesanza P, Ojembarrena Martinez E, Olaskoaga Arrate A. Version Española del ECBI (Eyberg Child Behavior Inventory): medida de validez. Atención Primaria. 1998; 21(2): 65-74.
34. Garcia-Tornel Florensa S, Calzada EJ, Eyberg SM, Mas Alguacil JC, Vilamala Serra C, Baraza Mendoza C, Villena Collado H, Gonzalez García, Calvo Hernández M, Trinxant Domenech A. Inventario de Eyberg Del comportamiento en niños. Normalización de la versión española y su utilidad para el pediatra extrahospitalario. Anal Esp Ped. 1998; 48 (5): 475-482.
35. Biederman J, Mick E and Faraone SV. Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom Type Am J Psychiatry 157:816-818, May 2000.
36. Barkley Russell A Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press. New York. 2006. Pag 651.
2. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. (Clinical guideline; no. 72). London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Sep. 59 p. http://guidance.nice.org.uk/CG72
3. Reason R; Working Party of the British Psychological Society. ADHD: a psychological response to an evolving concept. Report of a Working Party of the British Psychological Society. J Learn Disabil. 1999;32(1):85-91.
4. Report of a Working Party of The British Psychological Society. Attention Deficit/ Hyperactivity Disorder (AD/HD): Guidelines and principles for successful multi-agency working. Leicester UK: The British Psychological Society; 2000.
5. Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). Royal Australasian College of Psysicians. June 2009. [Consultado: 10/06/10]. http://www.nhmrc.gov.au/publications/ synopses/adhd_draft.htm
6. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, 1re édition, Toronto (ON), CADDRA, 2006. http://www.caddra.ca/ joomla/index.php?Itemid=70 / http://www.caddra. ca/cms4/index.php?option=com_content&view=a rticle&id=26&Itemid=353&lang=en
7. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology SAGE Publications Ltd. London http://www. bap.org.uk/docsbycategory.php?docCatID=2
8. Evidence Based Clinical Practice Guideline for Outpatient Evaluation and Management of Attention Deficit/Hyperactivity Disorder Guideline 27. Cincinnati Children’s Hospital Medical Center, Cincinnaty 2007. http://www.cincinnatichildrens. org/svc/alpha/h/health-policy/ev-based/adhd.htm
9. E. Taylor, M. Döpfner, J., P. Asherson, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, A. Rothenberger, E. Sonuga-Barke, H.-C. Steinhausen and A. Zuddas. Eur Child Adolesc Psychiatry 2004; [Suppl 1] 13:I/7–I/30.
10. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105(5): 1158-70.
11. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity, Disorder Committee on Quality, Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108(4): 1033-44.
12. Pliszka S in name of AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7):894-921
13. Winters NC, Pumariga A, Work Group on Community Child and Adolescent Psychiatry, Work Group on Quality Issues. Practice parameter on child and adolescent mental health care in community systems of care. J Am Acad Child Adolesc Psychiatry 2007; 46(2): 284-99.
14. Steiner H, Remsing L, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(1):126-41.
15. Plisszka S, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, et al and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-deficit/ Hyperactivity Disorder. The Texas Childrens Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/ Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2006; 45(6):642-657.
16. ICSI. Institute for Clinical Systems Improvements. ADHD, Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents, Diagnosis and Management (Guideline) 2007. (Actualizado 04/2010) [Consultado: 10/06/10]: http://www.icsi.org/adhd/adhd_2300. html
17. O’Brian JM, Felt BT, Van Harrison R, Paramjeet KA, Riolo SA, Shehab N. UMHS. University of Michigan Health System. Guidelines for Clinical Care: Attention-Deficit Hyperactivity Disorder. 2005. [Consultado: 10/06/10]. Disponible en: http://cme.med.umich.edu/pdf/guideline/ ADHD05.pdf
18. Sentara Behavioral Health Services Guideline for the Recognition of ADHD in Adults. Sentara Healthcare (SHC). Virginia VA. 2006.
19. Quick Reference Guide. Recommended Screening and Medication Treatment Guidelines for Child and Adolescent Patients with Attention Deficit Hyperactivity Disorder (ADHD). Albuquerque, New Mexico: Lovelace Health Plan and Presbyterian Health Plan: 2007. http://aappolicy.aappublications. org/cgi/reprint/pediatrics;105/5/1158.pdf
20. Du Paul GJ. ADHD identification and assessment: basic Guidelines for educators. Helping Children at Home and School II: Handouts for Families and Educators S8–17. National Association of School Psychologists. Bethesda, MD 2004. www.nasponline. org
21. Montañés-Rada F, Gangoso-Fermoso AB, Martinez- Granero MA. Fármacos para el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 48: 469-81.
22. Montañés-Rada F, Gastaminza Pérez X, Catalá MA et al. Consenso del grupo GEITDAH sobre el trastorno por déficit de atención/hiperactividad. Rev Neurol 2010; 51: 633-7.
23. Rosler M, Fischer R, Ammer R, Ose C, Retz W, on behalf of the study group A randomised, placebocontrolled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attentiondeficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009; 259(2):120-9. epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009;259(6):368.
24. Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13(Suppl l):193-l0l
25. Banaschevski T, Coghill D, Santosh P, et al. Longacting medication for the hiperkinetic disorder. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15: 476- 9.
26. Conners CK, Erhardt D, Sparrow E . CAARS Conners adult ADHD rating scales. 1999. MHS, New York
27. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV. 1998. Guilford, New York
28. Eyberg SM, Robinson EA. Conduct Problem Behavior: Standarization of a behavioural rating scale with adolescents. J Clin Child Psychology. 1983; 12(3) 347-354.
29. Eyberg SM, Ross AW. Assesement of Child Behaviour Problems: The Validation of a New Inventory. J Clin Child Psychology. 1978; (summer): 113-116.
30. Robinson EA, Eyberg SM, Ross AW. The standardization of an inventory of child conduct problems behaviors. J Clin Child Psychology. 1980; (spring) 22-28.
31. Farre-Riba A y Narbona J. Escalas de Conners en la evaluación del trastorno por deficit de atención con hiperactividad: Nuevo estudio factorial en niños españoles. Rev Neurol. 1997; 25 (138): 200- 204.
32. Amador Campos JA. Idiazbal Alecha MA, Aznar Casanova A,Peró Cebollero M. Estructura factorial de la escala de Conners para profesores en muestras comunitaria y clínica. Revista de Psicología General y Aplicada. 2003: 56 (2) 173.184.
33. Fernández de Pinedo R, Gorostiza Garaya E, LAfuente Mesanza P, Ojembarrena Martinez E, Olaskoaga Arrate A. Version Española del ECBI (Eyberg Child Behavior Inventory): medida de validez. Atención Primaria. 1998; 21(2): 65-74.
34. Garcia-Tornel Florensa S, Calzada EJ, Eyberg SM, Mas Alguacil JC, Vilamala Serra C, Baraza Mendoza C, Villena Collado H, Gonzalez García, Calvo Hernández M, Trinxant Domenech A. Inventario de Eyberg Del comportamiento en niños. Normalización de la versión española y su utilidad para el pediatra extrahospitalario. Anal Esp Ped. 1998; 48 (5): 475-482.
35. Biederman J, Mick E and Faraone SV. Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom Type Am J Psychiatry 157:816-818, May 2000.
36. Barkley Russell A Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press. New York. 2006. Pag 651.
© 2021 AEPNyA Todos los derechos reservados
